1869, Foreign: Volume 109:1
0000 - Gale Group | NCCO AsiaWest
Kevin W. Garey, Jinhee Jo, Anne J Gonzales-Luna, Brittany Lapin, Abhishek Deshpande, Elaine Wang, Brooke Hasson, Sissi V. Pham, Shirley P. Huang, Pat Ray Reese, Henry Wu, Elizabeth Hohmann, Paul Feuerstadt, Caterina Oneto, Charles S. Berenson, Christine U. Lee, Barbara McGovern, Lisa vonMoltke,
... evaluated. Objectives To explore the association of SER-109 compared with placebo on HRQOL in patients with ... 2020 and included 182 patients randomized to SER-109 or placebo groups. Interventions SER-109 or placebo (4 capsules once daily for 3 ... week 8. Results In this study, 182 patients (109 [59.9%] female; mean age, 65.5 [16.5] years) were randomized to SER-109 (89 [48.9%]) or placebo (93 [51.1%]) ... scores were similar between patients in the SER-109 and placebo groups (52.0 [18.3] vs ... Cdiff32 total score was higher in the SER-109 arm than placebo at week 1 (49.4% ...
Tópico(s): Nosocomial Infections in ICU
2023 - American Medical Association | JAMA Network Open
IEEE Xplore
Volume 109
0000 - Gale Group | NCCO BritishPolitics
Vincenzo Di Pilato, Giulia Codda, Claudia Niccolai, Edward Willison, Joshua L. C. Wong, Erika Coppo, Gad Frankel, Anna Marchese, Gian María Rossolini,
... novel K. pneumoniae carbapenemase (KPC)-3 variant (KPC-109). Antimicrobial susceptibility testing was performed by reference broth ... and Oxford Nanopore Technologies). Functional characterization of KPC-109 was performed to investigate the impact of KPC-109 production on the β-lactam resistance phenotype of ... OmpK36 porin alterations. Horizontal transfer of the KPC-109-encoding plasmid was investigated by conjugation and transformation ... novel 270-loop mutated KPC-3 variant (KPC-109; ins_270_KYNKDD). KPC-109 production mediated resistance/ ...
Tópico(s): Infections and bacterial resistance
2023 - Elsevier BV | International Journal of Antimicrobial Agents
Volume 109 : Jan. 23, 1851-Mar. 30, 1853
1853 - Gale Group | SASII
Vivek Subbiah, Sant P. Chawla, Anthony P. Conley, Breelyn A. Wilky, Anthony W. Tolcher, Nehal J. Lakhani, David Berz, Vasily Andrianov, William Crago, Monica Holcomb, Abrahim Hussain, Carson Veldstra, James Kalabus, Brianne O’Neill, Lane Senne, Emily Rowell, Analeah B. Heidt, Katelyn M. Willis, Brendan P. Eckelman,
... available. We present the preclinical characterization of INBRX-109, a third-generation death receptor 5 (DR5) agonist, ... findings from a phase I trial of INBRX-109 in unresectable/metastatic chondrosarcoma (NCT03715933).INBRX-109 was first characterized preclinically as a DR5 agonist, ... evaluated both in vitro and in vivo. INBRX-109 (3 mg/kg every 3 weeks) was then ... control rate, and PFS.In preclinical studies, INBRX-109 led to antitumor activity in vitro and in ... minimal hepatotoxicity. In the phase I study, INBRX-109 was well tolerated and demonstrated antitumor activity in ...
Tópico(s): Cell death mechanisms and regulation
2023 - American Association for Cancer Research | Clinical Cancer Research
Volume 109 : Jan. 23, 1851-Mar. 30, 1853
1853 - Gale Group | SASII
Mehmet Salih Aydın, Mehmet Ali Eren, Nida Uyar, Nazim Kankılıç, Hüseyin Karaaslan, Tevfik Sabuncu, Hakim Çelık,
... The counts of WBC (14.01 (9.16) × 109/L vs. 10.41 (5.82) × 109/L), PLT (393.35 (196.98) × 109/L vs. 312.05 (141.33) × 109/L), neutrophil (11.52 (8.75) × 109/L vs. 6.93 (5.96) × 109/L), PLR (226.04 (159.24) × 109/L vs. 153.12 (101.91) × 109/L), NLR (6.64 (6.93) vs. 3. ... 3.99)) and SII (2505.86 (3957.47) × 109/L vs. 1092.50 (1476.08) × 109/L), and the levels of CRP (14.12 ( ...
Tópico(s): Pressure Ulcer Prevention and Management
2023 - Elsevier BV | Journal of Orthopaedic Science
Springer Link
1869, Foreign: Volume 109:1
0000 - Gale Group | NCCO AsiaWest
Cong Zhang, Sisi Wei, Suli Dai, Xiaoya Li, Huixia Wang, Hongtao Zhang, Guogui Sun, Baoen Shan, Lianmei Zhao,
... like macrophage. Among those differentially expressed lncRNAs, NR_109 was further studied, for its function in M2- ... the condition medium or macrophages mediated by NR_109 on tumor proliferation, metastasis and TME remodeling both ... and in vivo. Moreover, we revealed how NR_109 interacted with far upstream element-binding protein 1 ( ... probe the correlation among the expression of NR_109 and related proteins, showing the clinical significance of NR_109. Results We found that lncRNA NR_109 was highly expressed in M2-like macrophages. Knockdown ...
Tópico(s): Immune Cell Function and Interaction
2023 - BMJ | Journal for ImmunoTherapy of Cancer
1869, Foreign: Volume 109:1
0000 - Gale Group | NCCO AsiaWest
... funded by Seres Therapeutics were published for SER-109. SER-109 is prepared from donor stool using ethanol treatment ... packaging the resulting Firmicutes spores into capsules. SER-109 is administered orally as four capsules (each ∼3 × ... recurrence-free compared with 88% of the SER-109 group. Commenting on the SER-109 phase 3 trial, Ari Grinspan (Icahn School of ... the FDA [to allow providers to prescribe SER-109]?”, Grinspan added, “and will [health] insurance cover it?” ... funded by Seres Therapeutics were published for SER-109. SER-109 is prepared from donor stool using ...
Tópico(s): Nosocomial Infections in ICU
2022 - Elsevier BV | The Lancet Microbe
1869, Foreign: Volume 109:1
0000 - Gale Group | NCCO AsiaWest
Danni Wang, Suning Wang, Hao Wu, Jiansheng Gao, Kairong Huang, Dan‐Hong Xu, RU Huang-yao,
... categories based on platelet counts (very low < 50 × 109/L, intermediate-low 50 × 109-100 × 109/L, low 100 × 109-150 × 109/L, and normal ≥ 150 × 109/L). A multivariate Cox proportional risk model was ... death, with a saturation effect predicted at 100 × 109/L. When platelet counts were below 100 × 109/L, the risk of sepsis 28-day death ... 90).When platelet count was less than 100 × 109/L, it was a strong predictor of the ... which is declined by 13% for every 10 × 109/L growth in platelets. When platelet counts reach ...
Tópico(s): Hemodynamic Monitoring and Therapy
2022 - Frontiers Media | Frontiers in Medicine
Directory of Open Access Books (DOAB)
1869, Foreign: Volume 109:1 Letter. From Higashi Kuze Chiujô. To Harry S. Parkes K.C.B.
0000 - Gale Group | NCCO AsiaWest
Mukesh K. Sriwastva, Zhongbin Deng, Bomei Wang, Yun Teng, Anil Kumar, Kumaran Sundaram, Jingyao Mu, Chao Lei, Gerald W. Dryden, Fangyi Xu, Lifeng Zhang, Jun Yan, Xiang Zhang, Juw Won Park, Michael L. Merchant, Nejat K. Egilmez, Huang‐Ge Zhang,
... for 15 days) at two different doses (2 × 109 and 1 × 1010 MBELNs/100 µl/dose/mouse/ ... single oral administration of DiR-labeled MBELNs (10 × 109 particles/mouse), DiR fluorescent signals were predominantly detected ... control, or increasing concentrations of MBELNs (2.5 × 109, 5 × 109, 7.5 × 109, 10 × 109 particles/ml). Exposure to MBELNs resulted in a ... observed at the lowest concentration of 2.5 × 109 particles/ml and a maximal 27-fold expression increase at 10 × 109 particles/ml. The data indicate that MBELNs are ... h. First, we found that MBELN treatment (5 × 109 particles/ml) increases levels of phosphorylated-AhR as ...
Tópico(s): Extracellular vesicles in disease
2022 - Springer Nature | EMBO Reports
1869, Foreign: Volume 109:1
0000 - Gale Group | NCCO AsiaWest
Shiran Shapira, Marina Ben Shimon, Mori Hay‐Levi, Gil Shenberg, Guy Choshen, Lian Bannon, Michael Tepper, Dina Kazanov, Jonathan Seni, Shahar Lev‐Ari, Michael Peer, Dimitrios Boubas, Justin Stebbing, Sotirios Tsiodras, Nadir Arber,
... A dose of either 5 × 108 or 1 × 109 EXO-mCD24 was administered by inhalation, once daily, ... vehicle-treated and eight animals treated with 1 × 109 EXO-mCD24 showed no effects on organ histology. ... A dose of either 5 × 108 and 1 × 109 exosomes/mouse (n = 8 mice/treated group in ... mCD24 exosome treatment, at 1 × 108 or 1 × 109 EXO-mCD24, once daily for 3 days and ... Animals in the high-dose treatment group (1 × 109 EXO-mCD24) presented a moderate lung injury, with ... CXCL1) was observed, in animals treated with 1 × 109 EXO-mCD24 in the sera (Fig 5, upper ...
Tópico(s): SARS-CoV-2 and COVID-19 Research
2022 - Springer Nature | EMBO Molecular Medicine
1869, Foreign: Volume 109:1 Letter. From Higashi Kuze Chiujô. To Sir Harry S. Parkes K.C.B.
0000 - Gale Group | NCCO AsiaWest
... 54 ± 2.40 0.190cc t Test. WBC (109/L) 6.9 (5.5–9.4) 9. ... 0.012a,ba Mann-Whitney U test. Platelets (109/L) 228.5 (183.0–292.0) 255. ... 0.004a,ba Mann-Whitney U test. Neutrophils (109/L) 4.8 (3.5–6.9) 7. ... 0.008a,ba Mann-Whitney U test. Lymphocytes (109/L) 1.1 (0.7–1.7) 0. ... 0.001a,ba Mann-Whitney U test. Monocytes (109/L) 0.6 (0.4–0.8) 0. ... 0) 0.680aa Mann-Whitney U test. Eosinophils (109/L) 0.04 (0.01–0.12) 0. ... 08) 0.422aa Mann-Whitney U test. Basophils (109/L) 0.02 (0.01–0.04) 0. ... or CRP. Age >70 years, neutrophils ≥10.2 × 109/L, and lymphocytes 70 years 10.431 2. ...
Tópico(s): Dermatological and COVID-19 studies
2022 - Wiley | Journal of Medical Virology